| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy.
|
Clin Infect Dis
|
2005
|
3.57
|
|
2
|
CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study.
|
Arch Intern Med
|
2003
|
3.41
|
|
3
|
Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study.
|
Lancet
|
2002
|
3.32
|
|
4
|
Association of alcohol consumption and HIV surrogate markers in participants of the swiss HIV cohort study.
|
J Acquir Immune Defic Syndr
|
2013
|
3.02
|
|
5
|
Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia.
|
J Infect Dis
|
2005
|
2.58
|
|
6
|
CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy.
|
Clin Infect Dis
|
2008
|
2.35
|
|
7
|
Unsafe sex and increased incidence of hepatitis C virus infection among HIV-infected men who have sex with men: the Swiss HIV Cohort Study.
|
Clin Infect Dis
|
2005
|
2.35
|
|
8
|
Incidence and risk factors for chronic elevation of alanine aminotransferase levels in HIV-infected persons without hepatitis b or c virus co-infection.
|
Clin Infect Dis
|
2010
|
2.17
|
|
9
|
Frequency and determinants of unprotected sex among HIV-infected persons: the Swiss HIV cohort study.
|
Clin Infect Dis
|
2010
|
2.12
|
|
10
|
Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008.
|
Arch Intern Med
|
2010
|
2.05
|
|
11
|
Mortality in the Swiss HIV Cohort Study (SHCS) and the Swiss general population.
|
Lancet
|
2003
|
1.94
|
|
12
|
Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders.
|
J Infect Dis
|
2005
|
1.93
|
|
13
|
CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial.
|
Lancet
|
2006
|
1.91
|
|
14
|
The HIV care cascade in Switzerland: reaching the UNAIDS/WHO targets for patients diagnosed with HIV.
|
AIDS
|
2015
|
1.84
|
|
15
|
Stable virulence levels in the HIV epidemic of Switzerland over two decades.
|
AIDS
|
2006
|
1.81
|
|
16
|
Durability and outcome of initial antiretroviral treatments received during 2000--2005 by patients in the Swiss HIV Cohort Study.
|
J Infect Dis
|
2008
|
1.76
|
|
17
|
Prevalence of unsafe sexual behavior among HIV-infected individuals: the Swiss HIV Cohort Study.
|
J Acquir Immune Defic Syndr
|
2003
|
1.70
|
|
18
|
Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy.
|
AIDS
|
2002
|
1.63
|
|
19
|
Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the Swiss HIV Cohort Study.
|
Antivir Ther
|
2007
|
1.55
|
|
20
|
Incidence and outcome of progressive multifocal leukoencephalopathy over 20 years of the Swiss HIV Cohort Study.
|
Clin Infect Dis
|
2009
|
1.53
|
|
21
|
Safety and efficacy of sperm washing in HIV-1-serodiscordant couples where the male is infected: results from the European CREAThE network.
|
AIDS
|
2007
|
1.50
|
|
22
|
Risk factors for anal cancer in persons infected with HIV: a nested case-control study in the Swiss HIV Cohort Study.
|
Am J Epidemiol
|
2013
|
1.48
|
|
23
|
ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir.
|
Pharmacogenet Genomics
|
2010
|
1.46
|
|
24
|
Association of pharmacogenetic markers with premature discontinuation of first-line anti-HIV therapy: an observational cohort study.
|
J Infect Dis
|
2010
|
1.45
|
|
25
|
Effect of early antiretroviral therapy during primary HIV-1 infection on cell-associated HIV-1 DNA and plasma HIV-1 RNA.
|
Antivir Ther
|
2011
|
1.44
|
|
26
|
A prospective trial of structured treatment interruptions in human immunodeficiency virus infection.
|
Arch Intern Med
|
2003
|
1.44
|
|
27
|
Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir.
|
AIDS
|
2012
|
1.42
|
|
28
|
Mitochondrial DNA and sperm quality in patients under antiretroviral therapy.
|
AIDS
|
2003
|
1.38
|
|
29
|
Effectiveness of protease inhibitor monotherapy versus combination antiretroviral maintenance therapy: a meta-analysis.
|
PLoS One
|
2011
|
1.38
|
|
30
|
Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study.
|
Antivir Ther
|
2005
|
1.36
|
|
31
|
Assessment of recent HIV-1 infection by a line immunoassay for HIV-1/2 confirmation.
|
PLoS Med
|
2007
|
1.33
|
|
32
|
JC virus-specific immune responses in human immunodeficiency virus type 1 patients with progressive multifocal leukoencephalopathy.
|
J Virol
|
2009
|
1.32
|
|
33
|
Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study.
|
Antivir Ther
|
2010
|
1.30
|
|
34
|
Infrequent transmission of HIV-1 drug-resistant variants.
|
Antivir Ther
|
2004
|
1.30
|
|
35
|
Tenofovir use is associated with an increase in serum alkaline phosphatase in the Swiss HIV Cohort Study.
|
Antivir Ther
|
2008
|
1.29
|
|
36
|
Contribution of 20 single nucleotide polymorphisms of 13 genes to dyslipidemia associated with antiretroviral therapy.
|
Pharmacogenet Genomics
|
2007
|
1.25
|
|
37
|
Resurgence of HIV infection among men who have sex with men in Switzerland: mathematical modelling study.
|
PLoS One
|
2012
|
1.25
|
|
38
|
Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial.
|
J Infect Dis
|
2003
|
1.25
|
|
39
|
Early antiretroviral therapy during primary HIV-1 infection results in a transient reduction of the viral setpoint upon treatment interruption.
|
PLoS One
|
2011
|
1.24
|
|
40
|
A genome-to-genome analysis of associations between human genetic variation, HIV-1 sequence diversity, and viral control.
|
Elife
|
2013
|
1.19
|
|
41
|
Systemic antibody responses to gut commensal bacteria during chronic HIV-1 infection.
|
Gut
|
2011
|
1.18
|
|
42
|
HIV transmission under highly active antiretroviral therapy.
|
Lancet
|
2008
|
1.17
|
|
43
|
Humoral immunity to HIV-1: kinetics of antibody responses in chronic infection reflects capacity of immune system to improve viral set point.
|
Blood
|
2004
|
1.14
|
|
44
|
Predicting the evolution of Kaposi sarcoma, in the highly active antiretroviral therapy era.
|
AIDS
|
2008
|
1.13
|
|
45
|
HIV-1 p24 may persist during long-term highly active antiretroviral therapy, increases little during short treatment breaks, and its rebound after treatment stop correlates with CD4(+) T cell loss.
|
J Acquir Immune Defic Syndr
|
2005
|
1.07
|
|
46
|
Ageing with HIV: medication use and risk for potential drug-drug interactions.
|
J Antimicrob Chemother
|
2011
|
1.04
|
|
47
|
Self-reported alcohol consumption and its association with adherence and outcome of antiretroviral therapy in the Swiss HIV Cohort Study.
|
Antivir Ther
|
2009
|
1.03
|
|
48
|
Interruptions of cART limits CD4 T-cell recovery and increases the risk for opportunistic complications and death.
|
AIDS
|
2011
|
1.02
|
|
49
|
A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection.
|
J Infect Dis
|
2002
|
0.99
|
|
50
|
Choice of Initial Combination Antiretroviral Therapy in Individuals With HIV Infection: Determinants and Outcomes.
|
Arch Intern Med
|
2012
|
0.98
|
|
51
|
The impact of pregnancy and menopause on CD4 lymphocyte counts in HIV-infected women.
|
AIDS
|
2002
|
0.98
|
|
52
|
Partners of people on ART - a New Evaluation of the Risks (The PARTNER study): design and methods.
|
BMC Public Health
|
2012
|
0.96
|
|
53
|
Impact of single nucleotide polymorphisms and of clinical risk factors on new‐onset diabetes mellitus in HIV‐infected individuals.
|
Clin Infect Dis
|
2010
|
0.94
|
|
54
|
Stable partnership and progression to AIDS or death in HIV infected patients receiving highly active antiretroviral therapy: Swiss HIV cohort study.
|
BMJ
|
2004
|
0.93
|
|
55
|
Virological and immunological responses to efavirenz or boosted lopinavir as first-line therapy for patients with HIV.
|
Antivir Ther
|
2009
|
0.92
|
|
56
|
Treatment and prognosis of AIDS-related lymphoma in the era of highly active antiretroviral therapy: findings from the Swiss HIV Cohort Study.
|
Antivir Ther
|
2007
|
0.91
|
|
57
|
Conventional tuberculin skin testing versus T-cell-based assays in the diagnosis of latent tuberculosis infection in HIV-positive patients.
|
AIDS
|
2007
|
0.90
|
|
58
|
Effects of cognitive behavioral stress management on HIV-1 RNA, CD4 cell counts and psychosocial parameters of HIV-infected persons.
|
AIDS
|
2008
|
0.88
|
|
59
|
Further research needed to support a policy of antiretroviral therapy as an HIV prevention initiative.
|
Antivir Ther
|
2013
|
0.87
|
|
60
|
Management of hepatitis C virus (HCV) infection in drug substitution programs.
|
Swiss Med Wkly
|
2011
|
0.85
|
|
61
|
A controlled trial of granulocyte macrophage-colony stimulating factor during interruption of HAART.
|
AIDS
|
2003
|
0.85
|
|
62
|
Cytotoxic HIV-1 p55gag-specific CD4+ T cells produce HIV-inhibitory cytokines and chemokines.
|
J Clin Immunol
|
2002
|
0.83
|
|
63
|
Low postseroconversion CD4 count and rapid decrease of CD4 density identify HIV+ fast progressors.
|
AIDS Res Hum Retroviruses
|
2010
|
0.83
|
|
64
|
Impact of pregnancy and menopause on CD4 cell counts.
|
J Acquir Immune Defic Syndr
|
2005
|
0.82
|
|
65
|
Body fat changes among antiretroviral-naive patients on PI- and NNRTI-based HAART in the Swiss HIV cohort study.
|
Antivir Ther
|
2005
|
0.81
|
|
66
|
Long-term virological response to multiple sequential regimens of highly active antiretroviral therapy for HIV infection.
|
Antivir Ther
|
2004
|
0.80
|
|
67
|
HAART improves quality of life: should we care about the quality of spermatozoa?
|
AIDS
|
2008
|
0.80
|
|
68
|
Randomized trial of a computerized coronary heart disease risk assessment tool in HIV-infected patients receiving combination antiretroviral therapy.
|
Antivir Ther
|
2010
|
0.80
|
|
69
|
Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study.
|
AIDS
|
2007
|
0.80
|
|
70
|
Long-term efficacy after switch from protease inhibitor-containing highly active antiretroviral therapy to abacavir, lamivudine, and zidovudine.
|
AIDS
|
2004
|
0.79
|
|
71
|
Risk of cardiovascular events and blood pressure control in hypertensive HIV-infected patients: Swiss HIV Cohort Study (SHCS).
|
J Acquir Immune Defic Syndr
|
2013
|
0.79
|
|
72
|
Small dense lipoproteins, apolipoprotein B, and risk of coronary events in HIV-infected patients on antiretroviral therapy: the Swiss HIV Cohort Study.
|
J Acquir Immune Defic Syndr
|
2012
|
0.78
|
|
73
|
Sexual risk behavior in HIV-infected injection drug users.
|
Clin Infect Dis
|
2004
|
0.78
|
|
74
|
No longitudinal mitochondrial DNA sequence changes in HIV-infected individuals with and without lipoatrophy.
|
J Infect Dis
|
2011
|
0.78
|
|
75
|
Replicative phenotyping adds value to genotypic resistance testing in heavily pre-treated HIV-infected individuals--the Swiss HIV Cohort Study.
|
J Transl Med
|
2011
|
0.78
|
|
76
|
B cells from HIV-infected patients with primary central nervous system lymphoma display an activated phenotype and have a blunted TNF-α response to TLR9 triggering.
|
AIDS Res Hum Retroviruses
|
2010
|
0.77
|
|
77
|
Hierarchical modeling gave plausible estimates of associations between metabolic syndrome and components of antiretroviral therapy.
|
J Clin Epidemiol
|
2008
|
0.77
|
|
78
|
The prevalence of erectile dysfunction and its association with antiretroviral therapy in HIV-infected men: the Swiss HIV Cohort Study.
|
Antivir Ther
|
2012
|
0.77
|
|
79
|
Unusually high HIV infectiousness in an HIV-, HCV- and HSV-2-coinfected heterosexual man.
|
Swiss Med Wkly
|
2009
|
0.77
|
|
80
|
The individualized genetic barrier predicts treatment response in a large cohort of HIV-1 infected patients.
|
PLoS Comput Biol
|
2013
|
0.77
|
|
81
|
Lack of clinical and scientific evidence to justify the systematic use of ICSI in HIV-serodiscordant couples wishing to conceive where the male partner is infected.
|
Fertil Steril
|
2009
|
0.76
|
|
82
|
Life expectancy in HIV-positive persons in Switzerland: matched comparison with general population.
|
AIDS
|
2016
|
0.75
|
|
83
|
Adverse events of raltegravir and dolutegravir: a prospective analysis of 4,041 HIV-infected individuals from the Swiss HIV Cohort Study.
|
AIDS
|
2017
|
0.75
|
|
84
|
[The Swiss HIV Cohort Study: from research to health care].
|
Ther Umsch
|
2004
|
0.75
|
|
85
|
Impact of coinfection with HIV-1 and GB virus C in patients receiving a ritonavir-boosted HAART regimen: a substudy to the MaxCmin1 trial.
|
J Acquir Immune Defic Syndr
|
2005
|
0.75
|
|
86
|
Discontinuation of enfuvirtide in heavily pretreated HIV-infected individuals.
|
HIV Clin Trials
|
2009
|
0.75
|
|
87
|
Patients with influenza A/H1N1v- associated pneumonia: the perspective of a tertiary care hospital in Switzerland.
|
Swiss Med Wkly
|
2010
|
0.75
|